Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
endocrine system diseases | D004700 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FORTAMET | Andrx Corporation | N-021574 RX | 2004-04-27 | 1 products, RLD |
GLUMETZA | Santarus | N-021748 RX | 2005-06-03 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
INVOKAMET XR | Johnson & Johnson | N-205879 RX | 2016-09-20 | 4 products, RLD, RS |
INVOKAMET | Johnson & Johnson | N-204353 RX | 2014-08-08 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JANUMET XR | Merck & Co | N-202270 RX | 2012-02-02 | 3 products, RLD, RS |
JANUMET | Merck & Co | N-022044 RX | 2007-03-30 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JENTADUETO XR | Boehringer Ingelheim | N-208026 RX | 2016-05-27 | 2 products, RLD, RS |
JENTADUETO | Boehringer Ingelheim | N-201281 RX | 2012-01-30 | 3 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
KOMBIGLYZE XR | AstraZeneca | N-200678 DISCN | 2010-11-05 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
QTERNMET XR | AstraZeneca | N-210874 DISCN | 2019-05-02 | 4 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SYNJARDY XR | Boehringer Ingelheim | N-208658 RX | 2016-12-09 | 4 products, RLD, RS |
SYNJARDY | Boehringer Ingelheim | N-206111 RX | 2015-08-26 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TRIJARDY XR | Boehringer Ingelheim | N-212614 RX | 2020-01-27 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
XIGDUO XR | AstraZeneca | N-205649 RX | 2014-10-29 | 5 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AVANDAMET | SB Pharmco | N-021410 DISCN | 2002-10-10 | 5 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
GLUCOVANCE | Bristol Myers Squibb | N-021178 DISCN | 2000-07-31 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
METAGLIP | Bristol Myers Squibb | N-021460 DISCN | 2002-10-21 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PRANDIMET | Novo Nordisk | N-022386 DISCN | 2008-06-23 | 2 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SEGLUROMET | Merck & Co | N-209806 RX | 2017-12-19 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZITUVIMET | Zydus Therapeutics | N-216743 RX | 2023-11-03 | 2 products, RLD, RS |
ZITUVIMET XR | Zydus Therapeutics | N-216778 RX | 2024-07-18 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
actoplus met | New Drug Application | 2025-03-27 |
alogliptin and metformin hydrochloride | NDA authorized generic | 2024-02-12 |
appformin | unapproved drug other | 2011-08-08 |
appformin-d | unapproved drug other | 2011-08-08 |
avandamet | New Drug Application | 2012-08-30 |
dapagliflozin and metformin hydrochloride | NDA authorized generic | 2024-12-20 |
fortamet | New Drug Application | 2010-03-15 |
glipizide and metformin hydrochloride | ANDA | 2018-12-11 |
glipizide and metformin hydrochloride glipizide and metformin hydrochloride | ANDA | 2024-12-04 |
glipizide and metformin hcl | ANDA | 2025-02-24 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Expiration | Code | ||
---|---|---|---|
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY, BOEHRINGER INGELHEIM | |||
2026-12-20 | PED | ||
2026-06-20 | NPP | ||
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY XR, BOEHRINGER INGELHEIM | |||
2026-12-20 | PED | ||
2026-06-20 | M-296 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO, BOEHRINGER INGELHEIM | |||
2026-12-20 | PED | ||
2026-06-20 | M-295 | ||
2023-03-30 | M-252 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO XR, BOEHRINGER INGELHEIM | |||
2026-12-20 | PED | ||
2026-06-20 | M-295 | ||
2023-03-30 | M-252 | ||
ERTUGLIFLOZIN / METFORMIN HYDROCHLORIDE, SEGLUROMET, MSD SUB MERCK | |||
2024-09-17 | M-275 | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET, MSD SUB MERCK | |||
2024-06-04 | PED | ||
2023-12-04 | M-187 | ||
2023-02-12 | PED | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET XR, MERCK SHARP DOHME | |||
2024-06-04 | PED | ||
2023-12-04 | M-187 | ||
2023-02-12 | PED |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Metformin Hydrochloride, Riomet Er, Sun Pharm | |||
9962336 | 2035-05-01 | DP | |
Empagliflozin / Linagliptin / Metformin Hydrochloride, Trijardy Xr, Boehringer Ingelheim | |||
9949998 | 2034-06-11 | U-2290, U-2731 | |
10258637 | 2034-04-03 | U-2290, U-2731 | |
11090323 | 2034-04-03 | U-3192, U-3193 | |
10596120 | 2032-03-07 | DP | U-2775, U-2776, U-2790, U-2792 |
11564886 | 2032-03-07 | DP | U-3531 |
10406172 | 2030-06-15 | DP | U-2733 |
9155705 | 2030-05-21 | DP | |
8551957 | 2029-10-14 | DP | U-2730 |
9415016 | 2029-04-02 | DP | |
10022379 | 2029-04-02 | U-2339, U-2732 | |
7579449 | 2028-08-01 | DP | |
7713938 | 2027-04-15 | DS, DP | |
8883805 | 2025-11-26 | DP | |
7407955 | 2025-05-02 | DS, DP | |
8119648 | 2023-08-12 | U-802, U-1652 | |
8178541 | 2023-08-12 | DP | U-775, U-1652, U-1853 |
Empagliflozin / Metformin Hydrochloride, Synjardy, Boehringer Ingelheim | |||
9949997 | 2034-05-17 | U-3532, U-3533 | |
10610489 | 2030-09-30 | DP | |
Linagliptin / Metformin Hydrochloride, Jentadueto Xr, Boehringer Ingelheim | |||
9555001 | 2033-03-06 | DP | U-1967, U-1968 |
9173859 | 2027-05-04 | DP | U-1503 |
Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab | |||
9616028 | 2030-11-12 | DP | |
8685934 | 2030-05-26 | U-1522 | |
7919598 | 2029-12-16 | DP | |
8501698 | 2027-06-20 | DP | U-493 |
6515117 | 2025-10-04 | DS, DP | U-493 |
Ertugliflozin / Metformin Hydrochloride, Segluromet, Msd Sub Merck | |||
9308204 | 2030-10-21 | DP | |
9439902 | 2030-10-21 | U-2214 | |
8080580 | 2030-07-13 | DS, DP | U-2214 |
Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms | |||
11576894 | 2030-07-06 | DP | |
7943582 | 2029-02-26 | DS, DP | U-493, U-2441, U-2632 |
8513202 | 2027-12-03 | DS, DP | U-493, U-2441, U-2632 |
7943788 | 2027-07-14 | DS, DP | |
8222219 | 2025-04-11 | U-493, U-2441, U-2632 | |
8785403 | 2024-07-30 | DP | |
Linagliptin / Metformin Hydrochloride, Jentadueto, Boehringer Ingelheim | |||
8846695 | 2030-06-04 | U-1503 | |
10973827 | 2029-04-02 | DP | |
8673927 | 2027-05-04 | U-1503 | |
Alogliptin Benzoate / Metformin Hydrochloride, Kazano, Takeda Pharms Usa | |||
8900638 | 2029-05-24 | DP | |
7807689 | 2028-06-27 | DS, DP | U-1337 |
8288539 | 2025-06-24 | DP | |
8173663 | 2025-03-15 | U-1338 | |
Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa | |||
9320714 | 2029-02-03 | DP | |
9101660 | 2027-01-22 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 151 | 230 | 500 | 318 | 229 | 1391 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 92 | 204 | 470 | 276 | 186 | 1193 |
Healthy volunteers/patients | — | — | — | 202 | 2 | — | 2 | 13 | 219 |
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 19 | 23 | 35 | 51 | 60 | 176 |
Syndrome | D013577 | — | — | 12 | 31 | 36 | 36 | 55 | 157 |
Obesity | D009765 | EFO_0001073 | E66.9 | 9 | 30 | 19 | 34 | 40 | 125 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | 9 | 28 | 22 | 28 | 22 | 100 |
Prediabetic state | D011236 | EFO_1001121 | R73.03 | 5 | 11 | 10 | 17 | 39 | 79 |
Gestational diabetes | D016640 | — | O24.4 | 3 | 6 | 18 | 13 | 26 | 62 |
Glucose intolerance | D018149 | HP_0000833 | R73.03 | 2 | 9 | 10 | 13 | 28 | 59 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 13 | 8 | 2 | — | 4 | 26 |
Adenocarcinoma | D000230 | — | — | 2 | 18 | 1 | — | 2 | 22 |
Carcinoma | D002277 | — | C80.0 | 5 | 17 | 3 | — | 1 | 22 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 11 | 4 | — | 3 | 19 |
Lung neoplasms | D008175 | — | C34.90 | 2 | 13 | 1 | — | 2 | 18 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 12 | 1 | — | 2 | 15 |
Colorectal neoplasms | D015179 | — | — | 2 | 9 | 3 | — | 1 | 15 |
Recurrence | D012008 | — | — | 2 | 4 | 2 | — | 2 | 9 |
Chronic renal insufficiency | D051436 | — | N18 | — | 6 | 3 | — | 2 | 9 |
Covid-19 | D000086382 | — | U07.1 | — | 2 | 4 | — | 2 | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 11 | — | — | 4 | 20 |
Leukemia | D007938 | — | C95 | 3 | 4 | — | — | 3 | 10 |
Squamous cell carcinoma | D002294 | — | — | 4 | 5 | — | — | 1 | 9 |
Melanoma | D008545 | — | — | 3 | 7 | — | — | — | 8 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 4 | 4 | — | — | 1 | 8 |
Glioblastoma | D005909 | EFO_0000515 | — | 2 | 6 | — | — | — | 8 |
Lymphoma | D008223 | — | C85.9 | 2 | 5 | — | — | — | 7 |
Sclerosis | D012598 | — | — | 2 | 6 | — | — | — | 7 |
Pharmacokinetics | D010599 | — | — | 5 | 1 | — | — | 1 | 7 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 2 | 6 | — | — | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 10 | — | — | — | 3 | 13 |
Therapeutic equivalency | D013810 | — | — | 10 | — | — | — | 2 | 12 |
Disease | D004194 | EFO_0000408 | R69 | 2 | — | — | — | 4 | 6 |
Drug interactions | D004347 | — | — | 5 | — | — | — | — | 5 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | 3 | 4 |
Microbiota | D064307 | — | — | 1 | — | — | — | 2 | 3 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 3 | — | — | — | — | 3 |
Fasting | D005215 | EFO_0002756 | — | 2 | — | — | — | 1 | 3 |
Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | 1 | 2 |
Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 5 | 5 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 2 | 2 |
Disease-free survival | D018572 | EFO_0000409 | — | — | — | — | — | 2 | 2 |
Ischemic stroke | D000083242 | — | — | — | — | — | — | 2 | 2 |
Fertilization in vitro | D005307 | — | — | — | — | — | — | 2 | 2 |
Essential hypertension | D000075222 | — | I10 | — | — | — | — | 2 | 2 |
Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | — | — | — | 2 | 2 |
Precocious puberty | D011629 | — | E22.8 | — | — | — | — | 2 | 2 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
Drug common name | Metformin |
INN | metformin |
Description | Metformin is a member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1. It has a role as a hypoglycemic agent, a xenobiotic, an environmental contaminant and a geroprotector. It is functionally related to a biguanide. It is a conjugate base of a metformin(1+). |
Classification | Small molecule |
Drug class | hypoglycemics (phenformin type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN(C)C(=N)NC(=N)N |
PDB | — |
CAS-ID | 657-24-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1431 |
ChEBI ID | 6801 |
PubChem CID | 4091 |
DrugBank | DB00331 |
UNII ID | 9100L32L2N (ChemIDplus, GSRS) |